4Q13

Apo Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant with a glucocorticoid receptor-interacting protein 1 NR box II peptide

Summary for 4Q13

Entry DOI	10.2210/pdb4q13/pdb
Related	4PXM 4PY1
Descriptor	Estrogen receptor, Glucocorticoid receptor-interacting protein 1 NR box II peptide (3 entities in total)
Functional Keywords	metastatic breast cancer, activating point mutation, drug resistance, serm resistance, alpha helix, nuclear hormone receptor, hormone binding protein-peptide complex, hormone binding protein/peptide
Biological source	Homo sapiens (human) More
Total number of polymer chains	4
Total formula weight	62631.76
Authors	Fanning, S.W.,Panchamukhi, S.,Greene, G.L. (deposition date: 2014-04-02, release date: 2015-04-08, Last modification date: 2024-02-28)
Primary citation	Fanning, S.W.,Mayne, C.G.,Dharmarajan, V.,Carlson, K.E.,Martin, T.A.,Novick, S.J.,Toy, W.,Green, B.,Panchamukhi, S.,Katzenellenbogen, B.S.,Tajkhorshid, E.,Griffin, P.R.,Shen, Y.,Chandarlapaty, S.,Katzenellenbogen, J.A.,Greene, G.L. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife, 5:-, 2016 Cited by PubMed: 26836308 DOI: 10.7554/eLife.12792 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.24 Å)

Structure validation